+

WO2000007582A3 - Utilisation de derives de thiazolidinedione pour le traitement ou la prevention de cataractes - Google Patents

Utilisation de derives de thiazolidinedione pour le traitement ou la prevention de cataractes Download PDF

Info

Publication number
WO2000007582A3
WO2000007582A3 PCT/US1999/013810 US9913810W WO0007582A3 WO 2000007582 A3 WO2000007582 A3 WO 2000007582A3 US 9913810 W US9913810 W US 9913810W WO 0007582 A3 WO0007582 A3 WO 0007582A3
Authority
WO
WIPO (PCT)
Prior art keywords
cataracts
prevention
treatment
thiazolidinedione derivatives
derivatives
Prior art date
Application number
PCT/US1999/013810
Other languages
English (en)
Other versions
WO2000007582A2 (fr
Inventor
John Hardwick Johnson
Original Assignee
Warner Lambert Co
John Hardwick Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, John Hardwick Johnson filed Critical Warner Lambert Co
Priority to AU46949/99A priority Critical patent/AU4694999A/en
Publication of WO2000007582A2 publication Critical patent/WO2000007582A2/fr
Publication of WO2000007582A3 publication Critical patent/WO2000007582A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La présente invention concerne une méthode d'utilisation de dérivés de thiazolidinone pour traiter ou prévenir les cataractes.
PCT/US1999/013810 1998-08-06 1999-06-18 Utilisation de derives de thiazolidinedione pour le traitement ou la prevention de cataractes WO2000007582A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU46949/99A AU4694999A (en) 1998-08-06 1999-06-18 Use of thiazolidinedione derivatives for the treatment or prevention of cataracts

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9551898P 1998-08-06 1998-08-06
US60/095,518 1998-08-06

Publications (2)

Publication Number Publication Date
WO2000007582A2 WO2000007582A2 (fr) 2000-02-17
WO2000007582A3 true WO2000007582A3 (fr) 2000-06-22

Family

ID=22252372

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/013810 WO2000007582A2 (fr) 1998-08-06 1999-06-18 Utilisation de derives de thiazolidinedione pour le traitement ou la prevention de cataractes

Country Status (5)

Country Link
AR (1) AR021749A1 (fr)
CO (1) CO5050324A1 (fr)
PE (1) PE20000946A1 (fr)
UY (1) UY25643A1 (fr)
WO (1) WO2000007582A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111511402A (zh) * 2017-12-28 2020-08-07 国立大学法人福井大学 白内障的预防剂及/或治疗剂、用于预防及/或治疗白内障的医药组合物、ppar活化剂的用于制造它们的用途、以及滴眼剂

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0139421A1 (fr) * 1983-08-30 1985-05-02 Sankyo Company Limited Dérivés de la thiazolidine, leur préparation et composition les contenant
JPS62234085A (ja) * 1985-12-18 1987-10-14 Sankyo Co Ltd チアゾリジン誘導体を有効成分とする糖尿病性合併症治療剤
EP0277836A1 (fr) * 1987-02-04 1988-08-10 Sankyo Company Limited Dérivés de la thiazolidinone leur préparation et leur application
WO1998010760A1 (fr) * 1996-09-12 1998-03-19 Sankyo Company, Limited Potentialisateur d'activite de glutathione-reductase contenant de la troglitazone
EP0869126A1 (fr) * 1997-04-02 1998-10-07 Sankyo Company Limited Dérivés de dithiolane leur préparation et leur effet thérapeutique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0139421A1 (fr) * 1983-08-30 1985-05-02 Sankyo Company Limited Dérivés de la thiazolidine, leur préparation et composition les contenant
JPS62234085A (ja) * 1985-12-18 1987-10-14 Sankyo Co Ltd チアゾリジン誘導体を有効成分とする糖尿病性合併症治療剤
EP0277836A1 (fr) * 1987-02-04 1988-08-10 Sankyo Company Limited Dérivés de la thiazolidinone leur préparation et leur application
WO1998010760A1 (fr) * 1996-09-12 1998-03-19 Sankyo Company, Limited Potentialisateur d'activite de glutathione-reductase contenant de la troglitazone
EP0869126A1 (fr) * 1997-04-02 1998-10-07 Sankyo Company Limited Dérivés de dithiolane leur préparation et leur effet thérapeutique

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Troglitazone, Noscal.RTM..", DRUGS OF THE FUTURE, (1995) 20/9 (974-976)., XP000853998 *
ARAKI, KAZUSI (1) ET AL: "Troglitazone suppresses diabetic nephropathy and cataract formation without decreasing plasma glucose and blood pressure in severely diabetic ZDF rats.", DIABETES, (1999) VOL. 48, NO. SUPPL. 1, PP. A138. MEETING INFO.: 59TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION SAN DIEGO, CALIFORNIA, USA JUNE 19-22, 1999 AMERICAN DIABETES ASSOCIATION., May 1999 (1999-05-01), XP000856147 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HORIKOSHI, HIROYOSHI ET AL: "Pharmaceutical compositions containing thiazolidine derivatives for the treatment of diseases related to diabetes", XP002123769 *
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YOKOYAMA, TOMIHISA ET AL: "Glutathione reductase activity potentiator containing troglitazone", XP002123768 *
DATABASE CHEMABS chemical abstracts service; "Dithiolan derivatives, their preparation, and their therapeutic effect as glutathione reductase enhancers" *
MADAR Z (REPRINT) ET AL: "EFFECT OF CS-045 ON CATARACT APPEARANCE IN SAND RAT MODEL FOR DIABETES TYPE-II", DIABETES, (MAY 1993) VOL. 42, SUPP. 1, PP. A198. ISSN: 0012-1797., XP000853997 *
YOKOYAMA, TOMIHISA ET AL: "Inhibition of galactose-induced cataractogenesis by troglitazone, a new antidiabetic drug with an antioxidant property, in rat lens culture", J. OCUL. PHARMACOL. THER. (1999), 15(1), 73-83, XP000853996 *

Also Published As

Publication number Publication date
CO5050324A1 (es) 2001-06-27
AR021749A1 (es) 2002-08-07
PE20000946A1 (es) 2000-10-18
WO2000007582A2 (fr) 2000-02-17
UY25643A1 (es) 1999-11-17

Similar Documents

Publication Publication Date Title
AU9040098A (en) Compounds and method for the prevention and treatment of diabetic retinopathy
AU2001260400A1 (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
AU2935200A (en) Compounds for the treatment of obesity
WO2001085093A3 (fr) Composes et methodes permettant la modulation de l'angiopathie cerebrale amyloide
WO2001044247A3 (fr) Agents et methodes de traitement des maladies hyperplasiques
MXPA03005699A (es) Derivados de tiazol para tratar trastornos relacionados con ppar.
AU3998400A (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
WO2001060347A3 (fr) Methode de traitement des douleurs oculaires
AU2207400A (en) A method for the prophylactic treatment of cataracts
HU9802721D0 (en) Method and composition for the treatment and prevention of hyperuricemia
AU3198699A (en) Method for the treatment of joint diseases characterized by unwanted pannus
AU2001284413A1 (en) Medicinal compositions for preventing or treating heart failure
AU7622000A (en) Compounds for the treatment of viral-mediated diseases
AU4694999A (en) Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
AU2001277534A1 (en) Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity
AU5038299A (en) Process for the biocidal treatment of surfaces
MXPA02012907A (es) Procedimiento para encontrar compuestos que son adecuados para el tratamiento y/o la profilaxia de la obesidad.
IL120443A0 (en) Heterocyclic compounds for the treatment of pancreatitis
AU2002218337A1 (en) Method for inducing cognition enhancement by use of trimethyl-bicyclo(2.2.1)heptane derivatives
AU7750100A (en) Method for the treatment of obesity
WO2001041709A3 (fr) Methodes de traitement de maladie et d'inflammation liees a la mort de cellule
WO2000007582A3 (fr) Utilisation de derives de thiazolidinedione pour le traitement ou la prevention de cataractes
WO2002083151A3 (fr) Compositions et procedes pour traiter un etat arthritique
AU2002215059A1 (en) Combination of amines and vanadium (IV)/(V) compounds for the treatment and/or prevention of diabetes mellitus
AU2182800A (en) Use of inhibitors of gag synthesis for the treatment of corneal haze

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载